Chadi Hage Chehade
@chadihcmd
Followers
350
Following
944
Media
29
Statuses
389
PGY1 @UofUInternalMed Former Post-Doctoral Research Fellow @Huntsmancancer @UUtah 🇺🇸 MD 23' @usjliban 🇱🇧🇫🇷
Salt Lake City, Utah
Joined August 2023
RT @urotoday: Delayed genomic testing limits access to life-prolonging cancer treatments. @chadihcmd @huntsmancancer joins @neerajaiims to….
0
6
0
RT @UofUInternalMed: Congrats to Dr. Chadi Hage Chehade on presenting at #ASCO25 on the timing and use of tumor next-generation sequencing….
0
2
0
RT @MedicalwatchFTW: 🌟🌎 #GlobalGUFriday.🧬 PARP inhibitors: from ovarian cancer to a pan-tumor approach — Landmark phase III trials transfor….
0
6
0
RT @CACancerJournal: PARP inhibitors comprise a therapeutic class that targets PARP proteins involved in DNA repair. This #OpenAccess revie….
0
38
0
RT @DRBakaloudiMD: Feeling Incredible honored to receive the #JQTF award!🌟.Huge thanks to my mentors @PGrivasMDPhD & JWright - Always inspi….
0
12
0
RT @ASCO: Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful….
0
21
0
RT @umangtalking: A very informative and detailed discussion on practice changing data and trial updates in bladder cancer by @PGrivasMDPhD….
0
5
0
RT @neerajaiims: Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in….
0
60
0
RT @HemOncToday: Real-world data show that only 30% to 40% of patients with the most common cancers receive NGS testing. 🗨️ “The ultimate….
healio.com
CHICAGO — The majority of patients with the most common advanced or metastatic cancers in the United States do not undergo next-generation sequencing testing, according to study results presented at...
0
1
0
RT @DrYukselUrun: Metformin did not boost survival in metastatic hormone-sensitive prostate cancer. It did ease ADT’s metabolic side effec….
0
21
0
RT @TheLancetOncol: ✏️@neerajaiims, @chadihcmd, and Georges Gebrael discuss the STAMPEDE trial in their linked comment. See here: https://t….
thelancet.com
The treatment of metastatic hormone-sensitive prostate cancer has changed substantially over the past decade, with androgen deprivation therapy (ADT) combined with androgen receptor pathway inhibit...
0
5
0
RT @PGrivasMDPhD: So honored to receive this prestigious award by @eaonc kudos to all investigators/staff who work hard to conduct trials….
0
22
0
RT @HemOncToday: The majority of patients with the most common advanced or metastatic #cancers in the United States do not undergo next-gen….
healio.com
CHICAGO — The majority of patients with the most common advanced or metastatic cancers in the United States do not undergo next-generation sequencing testing, according to study results presented at...
0
3
0
RT @urotoday: Real-world treatment delays between lutetium-177 and cabazitaxel in advanced #ProstateCancer. @YeonjungJoHCI & @umangtalking….
0
4
0
RT @DanaFarber_GU: GU Research Digest for the week of June 14 - 20: a selection of publications about GU cancers in high-impact journals. S….
0
10
0
RT @APCCC_Lugano: Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Pr….
0
16
0
Excited to see our work published in @CCR_AACR ! Real-world pts w/ mHSPC #prostatecancer w/ HRRalt had worse survival than those w/ non-altered HRR 👉�.Grateful for terrific support from team @RyonGraf @umangtalking @neerajaiims @urotoday @OncoAlert
Just in @CCR_AACR 👉Congrats @chadihcmd @umangtalking & @Huntsman_GU team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 @flatironhealth @FoundationATCG @RyonGraf 👉 need to add PARPi 👉free link: @OncoAlert @urotoday
9
23
72
RT @huntsmancancer: Our researchers made a strong showing at #ASCO25 —sharing bold ideas, breakthrough science, and real-world insights to….
0
4
0